Cargando…
Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review
BACKGROUND: Crohn’s disease (CD) and ulcerative colitis (UC) commonly affect women in their childbearing years. Vedolizumab (VDZ) is approved for treatment of moderate-to-severe CD and UC, but there is a knowledge gap regarding its use during pregnancy. This targeted literature review describes avai...
Autores principales: | Terjung, Birgit, Schmelz, Renate, Ehehalt, Robert, Klaus, Jochen, Knop, Jana, Schwind, Sabine, Wilke, Thomas, Stallmach, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580131/ https://www.ncbi.nlm.nih.gov/pubmed/33149762 http://dx.doi.org/10.1177/1756284820952592 |
Ejemplares similares
-
Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020) -
Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020) -
Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review
por: Fang, Shengbo, et al.
Publicado: (2022) -
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review
por: Helwig, Ulf, et al.
Publicado: (2020) -
Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
por: Crooks, Benjamin, et al.
Publicado: (2020)